Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”VTE and Cancer: A 20-Year Signal That Can’t Be Ignored.
In a nationwide Danish cohort of 138,049 first‑ever VTE patients (DVT 51.7%, PE 39.3%, SVT 8.9%), followed from 1996–2022, Søren Martiny et al. demonstrate a clear two‑phase cancer risk pattern after thrombosis.
Median age at VTE was 66 years, 52% were women, and 43.8% of events were provoked (≈48% by major factors such as recent surgery or fracture/trauma, the remainder by minor factors including pregnancy, HRT, hormonal contraception, or recent hospitalization).
At the time of the thrombotic event itself, all patients were cancer‑free (prior cancers other than non‑melanoma skin cancer were excluded), so any subsequent malignancy reflects incident cancer emerging after the index VTE rather than known active cancer at baseline.
Year One: The Occult Cancer Signal
During the first year after VTE, the absolute cancer risk was 4.0% and the standardized incidence ratio (SIR) versus the general population was 3.45 (95% CI 3.36–3.55), capturing both unprovoked and provoked events and holding across DVT, PE, and SVT.
The authors previously showed that this early excess is largely driven by cancers presenting within months of VTE, consistent with the concept of VTE as a harbinger of occult malignancy.
Years 2–20: The Persistent Cancer Risk
Beyond year one, cancer risk declines but remains 9–16% higher than expected for up to 20 years (SIR 1.09–1.16 across follow‑up windows), regardless of age group, sex, VTE type (SVT, DVT, or PE), primary vs secondary diagnosis, comorbidity burden, or whether the index event was provoked or unprovoked. After 20 years, the SIR approximates 1.00, suggesting the excess risk is time‑limited but clinically meaningful over two decades.
This long‑term signal is driven particularly by cancers linked to smoking, obesity, and alcohol—lung, pharynx, larynx, esophagus, stomach, liver, pancreas, colon—as well as haematologic malignancies, supporting the idea that VTE and cancer share upstream lifestyle and genetic determinants rather than a simple “occult cancer at baseline” explanation.”
Read the full article here.
Article: Venous Thromboembolism and 20-Year Cancer Risk: A Danish Population-Based Cohort Study
Authors: Søren K. Martiny, Vincent Lanting, Dóra K. Farkas, Nick van Es, Henrik T. Sørensen
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management
-
Apr 12, 2026, 21:24Heghine Khachatryan: Diagnosing PNH in Resource-Limited Settings
-
Apr 12, 2026, 21:15Katariina Öörni: Role of Cholesterol Absorption Efficiency in Atherosclerosis
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes